At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Deep Brain Stimulation (DBS) (device)
- How long the study runs
- Study runs about 297 months (dates as stated)
- About the drug or intervention
- Deep Brain Stimulation (DBS) — device: Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 1,500
- Started
- 2014-03-04
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for parkinson's disease
- • Clinical study - 1,500 participants
- • The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with parkinson's disease
Where?
- • Bristol - Southmead Hospital Bristol
- • Glasgow - Queen Elizabeth University Hospital
- • Liverpool - The Walton Centre
- • London - Charing Cross Hospital
- • +4 more UK sites
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS System in the treatment of Parkinson's disease. The utilization of Image Guided Programming (IGP), and other commercially available programming features, used as planning tools for the programming of patients with Boston Scientific's Vercise DBS System are also evaluated. Additionally, the utilization of the DBS Illumina 3D feature that may be used for the programming of patients with Boston Scientific's Vercise DBS Systems is also evaluated.
More detail
The purpose of this registry is to compile characteristics of world-wide outcomes for the use of Boston Scientific's commercially available Vercise DBS system in the treatment of Parkinson's disease. Subjects' improvement in disease symptoms and overall Quality of life will be assessed during the study following DBS and compared with baseline. Additionally, the utilization of Image Guided Programming (IGP) when used as a planning tool for programming of patients is also evaluated.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Meets criteria established in locally applicable Vercise System Direction for Use
- ✓At least 18 years old
Who cannot take part
- ✗Meets any safety concern in the Vercise System locally applicable Directions for Use
- ✗Subjects with significant cognitive or psychiatric impairment may be excluded in the evaluation of GXT.
See the full criteria
Where Is This Study? (8 UK sites)
Southmead Hospital Bristol
Bristol, United Kingdom
Queen Elizabeth University Hospital
Glasgow, United Kingdom
The Walton Centre
Liverpool, United Kingdom
Charing Cross Hospital
London, United Kingdom
King's College Hospital London
London, United Kingdom
St. Georges Hospital
London, United Kingdom
Royal Victoria Infirmary
Newcastle, United Kingdom
John Radcliffe Hospital
Oxford, United Kingdom
How to Get in Touch
Heleen Scholtes
Sponsor contactCONTACT
Alison Lewis
Sponsor contactCONTACT